BioGuard, the Patent Cliff and a Regulatory Deadline
Crestline Foods produces a chilled ready-meal line generating $62M in annual revenue. Its shelf-life system depends on a preservative blend supplied solely by BioGuard under a patent running to 2029. BioGuard is the only qualified source and supplies 100% of Crestline's requirement: 310 tonnes a year at $2.85 per kg. A new regulation lowers the permitted level of one component by 40%, effective in 14 months. BioGuard states that reformulating to the new limit will cost $1.4M and will only proceed if Crestline signs a 4-year take-or-pay at $3.60 per kg. Crestline's R&D has identified a plant-derived alternative from a second supplier at $4.10 per kg, but it needs 9 months of shelf-life validation and a $300,000 change to the filling line. Retail customers require 21-day shelf life and reserve the right to audit. Crestline's current BioGuard contract has 8 months remaining, no exit clause for regulatory change, and no volume flexibility.
1. Assess the supply risk and recommend whether Crestline should accept BioGuard's 4-year take-or-pay.
Read the worked answer
Characterize the risk first. This is a high-impact, high-likelihood event with a hard deadline: single source, 100% dependence, patent protection until 2029, no regulatory exit clause, and only 8 months of contract left. The regulatory change is certain, not speculative, so the question is not whether to act but which exposure to buy.
What accepting does. It secures compliance and continuity, transfers reformulation execution to the party that owns the chemistry, and converts an unknown cost into a known one. What it costs: a 4-year lock at $3.60 with take-or-pay, no volume flexibility, and continued 100% dependence on a supplier that has just demonstrated it can extract terms at a moment of maximum vulnerability. It also removes the urgency to qualify an alternative until 2029.
What rejecting does. It preserves optionality but leaves Crestline without a compliant product in 14 months unless the alternative validates in 9 months and the $300,000 line change is completed - a schedule with no float, and a validation failure would be catastrophic for a $62M line.
Recommendation: do not sign a 4-year take-or-pay as presented. Accept the reformulation and the price direction, but restructure the commitment: a 24-month term with an extension option, a price cap with indexation after year one, volume tolerance of plus or minus 15%, a regulatory-change termination right, and a milestone schedule with remedies if BioGuard misses the compliance date. In parallel, fund the alternative's validation now. A 24-month bridge buys the 9 months of validation plus a buffer, and it keeps a credible second source alive without betting the line on it.
2. Quantify the options and explain how the numbers should shape the recommendation.
Read the worked answer
Current baseline. 310 tonnes = 310,000 kg at $2.85 = $883,500 a year.
BioGuard proposal. 310,000 x $3.60 = $1,116,000, an increase of $232,500 a year, or $930,000 over four years before any volume effect. Treat the $1.4M reformulation cost as embedded in the price, not separate - if BioGuard also invoices it, the offer is materially worse and should be renegotiated.
Alternative alone. 310,000 x $4.10 = $1,271,000, an increase of $387,500 a year, plus $300,000 of capital in year 1. On pure price the alternative is $155,000 a year worse than BioGuard's proposal and carries validation risk.
Dual sourcing. Qualify the alternative for 30% of volume: 93,000 kg at $4.10 = $381,300, plus 217,000 kg from BioGuard at $3.60 = $781,200. Total $1,162,500, about $46,500 a year more than sole-sourcing BioGuard. That premium buys a qualified second source, negotiation leverage at each renewal, and protection if BioGuard's reformulation slips.
How the numbers shape the decision. The price gap between the two paths is small relative to the revenue at risk: 14 months of non-compliance on a $62M line dwarfs a $46,500 annual premium. The binding constraint is time, not cost. That argues for paying for optionality now - fund validation in parallel with a shortened BioGuard agreement - rather than optimizing the per-kg price and arriving at month 14 with one compliant source and no leverage. Set a decision gate at month 8: if validation has not passed, extend BioGuard on the best available terms rather than gamble on the deadline.
3. Which contract terms would you insist on in the BioGuard agreement, and why does each matter in this specific situation?
Read the worked answer
Regulatory-change clause. A defined process, cost-sharing formula, and termination or renegotiation right if a regulator changes permitted levels. Without it, Crestline is exposed to exactly the event now unfolding, with no remedy and an 8-month runway.
Term and exit. Reduce from four years to 24 months with a unilateral extension option. Justify it by the validation timeline: a 24-month bridge gives Crestline optionality without leaving BioGuard without a return on its $1.4M.
Volume tolerance and take-or-pay definition. Plus or minus 15% with a shortfall charge calculated on contribution margin, not on full price. A take-or-pay based on full price converts a demand dip into a pure penalty.
Performance milestones. A dated compliance plan with interim technical gates, a right to audit progress, and liquidated damages or termination if the reformulated product is not validated before the regulatory deadline. This is the clause that protects the $62M line.
IP and continuity. Ownership or a perpetual, royalty-bearing licence of the reformulation data and any Crestline-funded trials, plus step-in rights and access to the formulation through escrow if BioGuard fails. Crestline is paying for the reformulation through price, so it should not be a tenant in its own supply solution.
Quality and traceability. Specification by reference to the new limit, batch certification, audit rights responsive to retail customer audits, and a change-control clause preventing silent substitution.
Price mechanism. A cap for 24 months with indexation thereafter tied to named inputs, plus a benchmarking right. A flat $3.60 for four years is neither fair to BioGuard if inputs rise nor safe for Crestline if they fall.